Immuno-Oncology and Technology: Volume 9 to Volume 12

Title: IOTECH: Advancing Immuno-Oncology Research and Technology

Introduction: IOTECH, the sister journal to Annals of Oncology and ESMO Open, is the latest addition to the European Society for Medical Oncology’s esteemed collection of journals. Dedicated to publishing high-quality original research articles, reviews, perspectives, technology explained papers, letters to the editor, and editorials, IOTECH aims to serve as a prominent platform for leaders in the field of Immuno-Oncology.

Scope and Aims: As a quarterly publication, IOTECH is led by Editor-in-Chief, Professor John Haanen, and a distinguished international team of expert Editors and Editorial Board members. The journal focuses on pre-clinical and clinical studies, delving into natural and therapy-induced innate and adaptive immune responses against solid and haematological cancers. Moreover, IOTECH places a strong emphasis on technological advancements in Immuno-Oncology, seeking to highlight breakthroughs that decipher and enhance clinical outcomes.

Research and Technology Advancements: IOTECH’s diverse content encompasses a wide range of topics, from fundamental research on the immune response to cancer to cutting-edge technological innovations in Immuno-Oncology. By publishing original research articles and reviews, the journal provides a comprehensive view of the latest discoveries in the field. Perspectives and editorials further enrich the journal’s content, offering expert insights and analysis.

Technological Developments in Immuno-Oncology: A notable highlight of IOTECH is its focus on technological developments that shape the landscape of Immuno-Oncology. The journal showcases innovative approaches and breakthrough techniques that contribute to improved understanding and treatment of cancer. Technology explained papers provide in-depth discussions of these advancements, allowing readers to grasp the intricacies of novel methodologies.

Global Impact and Expert Leadership: IOTECH’s global reach is bolstered by its affiliation with Annals of Oncology and ESMO Open, ensuring its research is accessible to a broad international audience. The journal’s expert leadership, led by Professor John Haanen and the Editorial Board, ensures the publication of high-quality, impactful content.

Conclusion: IOTECH stands at the forefront of Immuno-Oncology research and technology. By offering a platform for leading researchers and clinicians to share their groundbreaking work, the journal plays a pivotal role in advancing our understanding of immune responses against cancer. With its focus on technological advancements and clinical outcomes, IOTECH contributes significantly to the progress of Immuno-Oncology, ultimately benefiting cancer patients worldwide.

Volume 9: March 2021

Volume 10: June 2021

Volume 11: October 2021

Volume 12: December 2021